e.p.t.q. Benelux

JETEMA continuously researches to maximize safety improvement.

ZEEP Technology (Zero Endotoxin & BDDE Entire Process)

e.p.t.q. keeps endotoxin below 0.1 EU/ml and no detection of residual BDDE minimizing various side effects that may occur after the procedure.


Ref. COA Certificate of Analysis                                                                                                                                                                                                   Endotoxin ▼  Inflammation ▼ /  BDDE ▼   Allergic reaction ▼

Downing Process

e.p.t.q. produces a uniform particle size through its own Downing Process.
Exquisite procedures are possible without agglomeration.


Ref. Data on file

Clinical Results

 Efficacy Assessment 
 From the WSRS results (reduced compared to the baseline scores) evaluated by independent expert panels and blinded investigators, we are able to see the wrinkle improvement of the group.


WSRS mean value change at 8, 16 and 24 weeks compared to baseline assessed by blinded investigators.

 Safety Assessment 
 No major abnormalities were reported, and slight abnormal responses from medical devices, such as slight swelling and pain for 2-3 days, were all recovered without any special treatment. There were no signs of abnormal vital signs, physical examinations, or blood tests. e.p.t.q. has been reported to be a safe medical device due to its proven safety in the body.

Ref. Clinical Study Result, Department of Dermatology, Chung-Ang University Hospital, Korea 2016